Sustained delivery of a HIF-1 antagonist for ocular neovascularization. - Wikidata - wikimedia - TriplyDB

Sustained delivery of a HIF-1 antagonist for ocular neovascularization.

Sustained delivery of a HIF-1 antagonist for ocular neovascularization.

http://www.wikidata.org/entity/Q30560557

about

Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery Aloe-emodin suppresses hypoxia-induced retinal angiogenesis via inhibition of HIF-1α/VEGF pathway Formononetin, an active compound of Astragalus membranaceus (Fisch) Bunge, inhibits hypoxia-induced retinal neovascularization via the HIF-1α/VEGF signaling pathway Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye.Nanoengineering of therapeutics for retinal vascular disease.Molecular pathogenesis of retinal and choroidal vascular diseases.Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits Inhibition of Hypoxia-Induced Retinal Angiogenesis by Specnuezhenide, an Effective Constituent of Ligustrum lucidum Ait., through Suppression of the HIF-1α/VEGF Signaling Pathway.HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies.Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases.Probable Chemical Hypoxia Effects on Progress of CNV Through Induction of Promoter CpG Demethylation and Overexpression of IL17RC in Human RPE Cells.The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization.Systems biology of oxygen homeostasis.HIF is not essential for suppression of experimental tumor growth by mTOR inhibition.Diosmetin protects against retinal injury via reduction of DNA damage and oxidative stress.AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration.Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration.Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage.Retinal and choroidal angiogenesis: a review of new targets.Prospects for early investigational therapies for sickle cell disease.

P2860

Q27007119-7A8A152E-2A9C-4206-9218-78D00FD7B414 Q28820904-A5E04893-F9DF-4CDB-8714-CA698F1CE810 Q28828440-FB6F3295-05F8-46AF-9E27-6F4A2986DEE3 Q35262576-92C001F3-9E77-45DD-8B68-61985B1B1BF2 Q35645705-7ECE64D5-AE65-45E2-8898-42449AF6109F Q36296789-1A87D16B-DE2C-4A5A-B13B-994BC210553D Q37383794-698FAC68-9FDC-4E15-AD48-116688B33EED Q38724669-F6151150-2E61-402E-A046-62E993BCCC93 Q38825960-209E79C3-D266-434B-AC9B-9760EF101686 Q38829320-B470D9C2-1BA2-431C-ABEE-A5283B833095 Q38924650-64C26FFE-4B64-42C0-93B2-447BA083BD3A Q39076235-C35DE837-A680-4AE6-AD07-9421F6C1A841 Q39145122-6DF2756D-1BB7-4E17-9F03-404F47085EB0 Q41396055-6A2A4EBA-48B2-47F8-A962-AF7C2C8A4E74 Q41679754-E35855FC-DEF9-4B5A-8220-CC09D120430B Q47225954-B24FF711-8D1F-45CB-A4EE-EAC7842CDE73 Q47442388-FDBC2334-CC3C-40E7-AFE9-51AFC0A7D81A Q47834991-AA712E82-FA9E-4796-9510-A7B17F379629 Q49334226-400F883A-9C68-454A-8459-A21A87A30B35 Q53098522-576607A5-D577-4A45-A644-D60324DEA973 Q53608275-684DF790-F958-48E1-A579-5F4E9A3FD709

P2860

Sustained delivery of a HIF-1 antagonist for ocular neovascularization.

http://www.wikidata.org/entity/Q30560557

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Sustained delivery of a HIF-1 antagonist for ocular neovascularization.

@ast

Sustained delivery of a HIF-1 antagonist for ocular neovascularization.

@en

type

label

Sustained delivery of a HIF-1 antagonist for ocular neovascularization.

@ast

Sustained delivery of a HIF-1 antagonist for ocular neovascularization.

@en

prefLabel

Sustained delivery of a HIF-1 antagonist for ocular neovascularization.

@ast

Sustained delivery of a HIF-1 antagonist for ocular neovascularization.

@en

P1433

Q30560557-CB05997A-5D75-42AF-80E7-C78DDF7E7468

P1476

Q30560557-4306B8EB-7D0B-4FD7-A8EA-67F8985E9D4F

P2093

Q30560557-0BDD2331-A318-4F7F-AF24-5EB313032402

Q30560557-16DDED21-E27E-4868-BFD6-D91412C8F1F3

Q30560557-1A0CCEAE-02ED-4CDF-88AB-7B81DBC96A5B

Q30560557-1C30ADF4-2CD1-42D3-9A26-7073683C8BF2

Q30560557-21513D90-DF55-4EA0-A002-5A14129D7CF3

Q30560557-54B0D783-E71A-49B0-9F5B-967D7CA88AD3

Q30560557-5AFDD5C2-5F29-4567-902D-2863033F4A7E

Q30560557-7A19F5FC-2EA6-41E1-A6B6-812EFE02A26D

Q30560557-7B195ADE-F626-4683-9A50-F20494945E24

Q30560557-AE4D5589-8C79-49A0-87ED-9F09D2778A2F

P2860

Q30560557-0680F51D-691F-4511-97CA-097583C7A810

Q30560557-0741D1CD-BE47-4DED-9BF6-3381129EDC42

Q30560557-141A757E-8723-4A49-A4EC-A5F101B25075

Q30560557-1487A9F5-7B70-4A7E-899C-5D7A542E1D83

Q30560557-16422D94-E1B3-45E4-AB47-69F0E6C12AA8

Q30560557-166329B8-1FB6-4087-8D88-27162CAF8CA7

Q30560557-1C03A317-A466-4E45-BF2A-08649D18413B

Q30560557-21BDCF4B-B515-4C81-95CE-29F7E298D4F7

Q30560557-29145ABC-A2C3-4FFE-A049-29ECCFE2214C

Q30560557-3F140468-CA41-4A36-BD5B-AA8F37EDE548

P304

Q30560557-E8F6A877-7EF3-4E6E-8D1B-4DBF4AF94496

P31

Q30560557-0EE594FA-A9D3-4598-867C-3DBD776E0067

P356

Q30560557-0A518187-AF26-45A7-A5A9-068B50C53716

P407

Q30560557-09F0CD9D-324C-4D8F-A9B0-C2596AFE5A6D

P433

Q30560557-72CE9D36-4C7B-4816-A7A0-8029F9738D9E

P478

Q30560557-058573FE-2BAD-477D-8AE1-123CA3905171

P50

Q30560557-6F5C4A76-3E3E-4837-AB2B-85BE10F3FC3D

Q30560557-B3846165-AF6B-414F-8B58-C3E5DE2893E6

Q30560557-FF704F00-3FD8-44F5-B20B-EE2F8E3E1478

P577

Q30560557-AD609BDC-3722-47A5-AC8C-C31919BE7058

P698

Q30560557-726C3C25-139A-4AD6-A332-91EDE687A71F

P921

Q30560557-BAD6C482-824B-4A3A-82B4-7265032916BC

P932

Q30560557-27CA2772-E5FE-4606-9AFF-8E29006BA7BA

P356

J.JCONREL.2013.10.008

P1433

Journal of Controlled Release

P1476

Sustained delivery of a HIF-1 antagonist for ocular neovascularization.

@en

P2093

Akiko Miki

http://www.w3.org/2001/XMLSchema#string

Bing Han

http://www.w3.org/2001/XMLSchema#string

Brian Oveson

http://www.w3.org/2001/XMLSchema#string

Christopher Seidel

http://www.w3.org/2001/XMLSchema#string

Daisuke Muramatsu

http://www.w3.org/2001/XMLSchema#string

Jie Fu

http://www.w3.org/2001/XMLSchema#string

Jikui Shen

http://www.w3.org/2001/XMLSchema#string

Lili Lu

http://www.w3.org/2001/XMLSchema#string

Mingsheng Wu

http://www.w3.org/2001/XMLSchema#string

Noriyasu Hashida

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization

Ranibizumab for neovascular age-related macular degeneration

VEGF is major stimulator in model of choroidal neovascularization.

Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model.

VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.

Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.

P304

625-633

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JCONREL.2013.10.008

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

172

http://www.w3.org/2001/XMLSchema#string

P50

Gregg L. Semenza

P577

2013-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24126220

http://www.w3.org/2001/XMLSchema#string

P921

neovascularization

P932

3871855

http://www.w3.org/2001/XMLSchema#string